{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 1: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 2: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 3: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"OG000","title":"Phase I - Part 1"},{"description":"Phase I Part 2 Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.\n\nPhase 2: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG001","title":"Phase 2 (Includes Phase I - Part 2 Participants)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"For this outcome measure the Phase I - Part 2 participants were combined with the Phase 2 participants as they received the same dosing regimen. Phase I - Part 1 participants were not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Through 30 days after completion of treatment (median number of cycles was 9.5 (range 1-34))","title":"Phase 2 - Toxicity of Carfilzomib in Combination With PLD and Dexamethasone as Measured by Number of Participants Who Experience Grade 3/4 Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}